Regulators expand review time for Novartis' MS drug
admin 3rd June 2020 Uncategorised 0Regulatory action is now expected in September 2020 More: Regulators expand review time for Novartis' MS drug Source: News
read moreRegulatory action is now expected in September 2020 More: Regulators expand review time for Novartis' MS drug Source: News
read moreIt will reiterate the need for those who have been close to someone testing positive for coronavirus to self-isolate More: Gov't launches public info campaign for track and trace Source: News
read moreBemcentinib was selected as the first candidate to be tested as part of the UK ACcelerating COVID-19 Research & Development platform (ACCORD) study More: First patient dosed in bemcentinib COVID-19 trial Source: News
read moreTecentriq in combination with Avastin is the first and only cancer immunotherapy regimen cleared to treat unresectable or metastatic liver cancer More: Roche's Tecentriq/Avastin combo wins US approval Source: News
read moreMultiple myeloma is the second most common blood cancer, with around 40,000 new cases per year in Europe More: Sanofi's Sarclisa cleared in Europe for multiple myeloma Source: News
read moreSanofi’s Sarclisa, chasing Darzalex, brings the heat with big myeloma combo win chelfand Tue, 06/02/2020 – 11:42 More: Sanofi's Sarclisa, chasing Darzalex, brings the heat with big myeloma combo win Source: fierce
read more© 1994 - 2024 B.M. Pharmaceuticals